GeniCore Biotech Unveils Its AI-Powered Genimer™ Aptamer Platform
Exhibitor: LIS TECH CO., LTD. / GENICORE BIOTECH
Date: 2026-06-03
Booth No.: M1231
GeniCore Biotech will showcase its proprietary Genimer™ Aptamer Platform at this year's biotechnology exhibition, demonstrating how AI-assisted molecular modeling and SELEX-based screening are transforming the development of aptamers, also known as "chemical antibodies." The platform is designed to overcome key limitations of conventional antibodies, including high production costs, batch-to-batch variability, and lengthy development timelines.
Unlike traditional antibodies that rely on biological production processes, Genimer™ aptamers are fully chemically synthesized, enabling superior consistency, minimal batch variation, and accelerated development. By integrating AI-driven design with advanced screening technologies, GeniCore Biotech is driving the next generation of standardized and scalable biomolecular tools for research and diagnostic applications.
Four Core Product Applications
Exosome Detection Kits (CD9 / CD63 / CD81)
Highly sensitive detection of exosome surface markers with minimal sample requirements and exceptional batch-to-batch consistency.
Exosome Isolation Kits (CD9 / CD63)
Deliver up to 2.5-fold higher recovery efficiency while preserving up to 98% exosome structural integrity, with no antibody-derived contamination.
His-Tag Protein Purification Kits
Featuring a metal ion-free design and gentle elution process, the system provides high-purity protein isolation with improved specificity and preserved biological activity.
PD-L1 Cell Staining Kits
Optimized staining chemistry reduces assay time, minimizes immune-related interference, and improves staining consistency and workflow efficiency.
Three Customized Service Solutions
Custom Aptamer Development
Combining AI-assisted design and NGS-enabled screening to accelerate aptamer discovery and overcome the limitations of conventional SELEX workflows.
ELASA Target Analysis Services
Providing picomolar (pM)-level sensitivity with over 50% background reduction for highly accurate target detection and quantification.
Exosome Characterization Services
Comprehensive exosome analysis featuring 40 nm resolution, multi-marker profiling, and detailed analytical reports for research and development applications.
Building the Next Generation Biomolecular Platform
Powered by fully synthetic aptamer technology and AI-driven molecular design, the Genimer™ Platform delivers robust, scalable, and reproducible solutions for biomolecular detection and research. GeniCore Biotech is committed to advancing the adoption of aptamer technologies and accelerating the transition toward next-generation bioanalytical and diagnostic tools.
Contact Information
Company Name: GeniCore Biotech Co., Ltd.
Official Website: https://www.geni-core.com/
Phone: +886-2-2228-8950
Email: info@geni-core.com
Booth Number: M1231
More Exhibitor's Press Release
- MarkerX Unveils AI-Driven Next-Gen Mass Spec Proteomics Platform in Strategic Alliance with Nanomics MARKER X CO., LTD. / 2026-07-15
- Dasher Neuroscience Signs MOU with Norwegian Research Center to Join the Platform Trial HYDRA DASHER NEUROSCIENCE HOLDINGS INC. / 2026-07-15
- Dasher-KY Progresses Phase II AI Drug for MSA, Initiating International Licensing Steps DASHER NEUROSCIENCE HOLDINGS INC. / 2026-07-15
- TaiMed Launches "Rooting for Love" Charity Campaign in Support of Taiwan Lourdes Association TAIMED BIOLOGICS INC. / 2026-07-15
- Exhibition Preview | Youlin Pharma sincerely invites you to attend BIO Asia-Taiwan 2026 SHANGHAI UNIONCLIN CO,. LTD.(UNIONCLIN) / 2026-07-14
- MicroDoctor Cosmetics Showcases Advanced Dissolving Microneedle Technology at BIO Asia MICRODOCTOR BIOMEDICAL CORPORATION / 2026-07-14
- Wireless × Complete Recording × Traceability BrainChild DRS Powers Smarter Decisions BRAINCHILD ELECTRONIC CO., LTD. / 2026-07-14
- BrainChild PRV2.0 Precision Measurement Built for Accuracy, Reliability and Better Decisions BRAINCHILD ELECTRONIC CO., LTD. / 2026-07-14
- TaiMed unveil NextGen TMB-365 CD4-Targeted ADC Platform for HIV Functional Cure at 2026 BIO Asia TAIMED BIOLOGICS INC. / 2026-07-13
- Italian Trade Agency (ITA) in BIO ASIA 2026 -EXOLAB ITALIAN ECONOMIC, TRADE AND CULTURAL PROMOTION OFFICE IN TAIPEI TRADE SECTION / 2026-07-13
- Italian Trade Agency (ITA) in BIO ASIA 2026 - MENARINI ITALIAN ECONOMIC, TRADE AND CULTURAL PROMOTION OFFICE IN TAIPEI TRADE SECTION / 2026-07-13
- Italian Trade Agency (ITA) in BIO ASIA 2026 - DEAKOS ITALIAN ECONOMIC, TRADE AND CULTURAL PROMOTION OFFICE IN TAIPEI TRADE SECTION / 2026-07-13
- Taiwan Bio partners with Terumo Blood and Cell Technologies to advance automated Treg manufacturing TERUMO BCT ASIA PTE. LTD. / 2026-07-13
- Terumo BCT and Steminent Collaborate to Advance MSC Late-Stage Clinical Manufacturing TERUMO BCT ASIA PTE. LTD. / 2026-07-13
- Terumo Blood and Cell Technologies Introduces APAC CGT Ecosystem Blueprint TERUMO BCT ASIA PTE. LTD. / 2026-07-13
- [Exhibition News] UVAT to Showcase Breakthrough Technologies at BIO Asia-Taiwan 2026! UVAT TECHNOLOGY CO., LTD. / 2026-07-09
- Painless Decoding, Seamless Tracking: Letting Singular Wings Medical's AI Navigate Your Metabolism. SINGULAR WINGS MEDICAL / 2026-07-08
- TaiMed showcase CD4-Targeted platform breakthroughs and High-Quality CDMO Solutions at 2026 BIO Asia TAIMED BIOLOGICS INC. / 2026-07-08
- Lonza Advances Integrated DNA to IND Programs Through Acceleration, De-Risking, and Innovation LONZA / 2026-07-08
- Lonza Acquires Rights to Nona Biosciences’ TfR1 Blood-Brain Barrier Technology and Expands Strategic LONZA / 2026-07-08